PA
CLSD

Perceptive Advisors’s Clearside Biomedical CLSD Stock Holding History

Perceptive Advisors’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-47,172
Closed -$7.6M – 122
2018
Q2 		$7.6M Sell
47,172
-507
-1% -$85.5K 0.2% 66
2018
Q1 		$7.68M Buy
47,679
+6,334
+15% +$772K 0.22% 70
2017
Q4 		$4.34M Hold
41,345
– – 0.14% 75
2017
Q3 		$5.15M Hold
41,345
– – 0.2% 69
2017
Q2 		$5.65M Sell
41,345
-6,126
-13% -$736K 0.28% 64
2017
Q1 		$5.65M Hold
47,471
– – 0.32% 58
2016
Q4 		$6.37M Buy
47,471
+5,151
+12% +$1.29M 0.45% 51
2016
Q3 		$11M Sell
42,320
-1
-0% -$122 0.71% 35
2016
Q2 		$4.45M Buy
+42,321
New +$4.44M 0.31% 63

Other funds holding CLSD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Perceptive Advisors's CLSD Position: Q3 2018 in Review

Perceptive Advisors sold out of Clearside Biomedical (CLSD) in Q3 2018, closing a stake of 47,172 shares — an estimated $7.6M sold.

Perceptive Advisors first reported a position in CLSD in Q2 2016 and held it in 9 quarters. The position peaked at $11M in Q3 2016. 89 funds tracked by Wall St. Rank hold CLSD as of Q3 2018.

  • Perceptive Advisors reported no remaining Clearside Biomedical position as of Q3 2018 after selling out during the quarter.
  • Perceptive Advisors sold 47,172 Clearside Biomedical shares in Q3 2018, an estimated $7.6M.
  • Perceptive Advisors first reported a position in Clearside Biomedical in Q2 2016 and held it in 9 quarters.
  • Perceptive Advisors's Clearside Biomedical position peaked at $11M in Q3 2016.
  • 89 funds tracked by Wall St. Rank held Clearside Biomedical as of Q3 2018.

Based on Perceptive Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.